Alvotech SA
Ouvert
SecteurSoins de santé
4.26 2.16
Résumé
Variation du prix de l'action
24h
Min
4.18
Max
4.32
Revenu | 110M 1M |
|---|---|
Ventes | -60M 106M |
P/E Moyenne du Secteur | 42.4 49.052 |
BPA | -0.09 |
Marge bénéficiaire | 0.973 |
Employés | 1,279 |
EBITDA | 134M 20M |
Recommandations | Neutre |
|---|---|
Prévisions sur 12 Mois | +11.99% upside |
Prochains Résultats | 19 août 2026 |
|---|
Capitalisation Boursière | 309M 1.3B |
|---|---|
Ouverture précédente | 2.1 |
Clôture précédente | 4.26 |
Sentiment de l'Actualité
By Acuity
17%
83%
27 / 342 Classement par Healthcare
Alvotech SA Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
À Propos Alvotech SA
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.